Company Encyclopedia
View More
name
Lyra Therapeutics
LYRA.US
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand.
4.514 T
LYRA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
E
PharmaceuticalsIndustry
Industry Ranking183/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-404.48%E
    • Profit Margin-5491.17%E
    • Gross Margin-16088.00%E
  • Growth ScoreE
    • Revenue YoY-59.21%E
    • Net Profit YoY66.25%A
    • Total Assets YoY-44.50%E
    • Net Assets YoY-120.99%E
  • Cash ScoreD
    • Cash Flow Margin-1.82%D
    • OCF YoY-59.21%E
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreE
    • Gearing Ratio109.90%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Perceptive Advisors Llc Sells 8,745 Shares of Lyra Therapeutics (NASDAQ:LYRA) Stock

    Perceptive Advisors LLC sold significant shares of Lyra Therapeutics, reducing its stake by 69.40%. The stock traded near its 12-month low at $3.90. Lyra's Q3 EPS beat estimates but missed on revenue. Analysts rate the stock as "Reduce." Bank of America increased its stake in Lyra by 33.7%. Institutional investors own 95.62% of Lyra's stock.

    Market Beat·
    US
    LYRA
    +7.40%
    Market Beat·
    US
    LYRA
    +7.40%

    Perceptive Advisors LLC Disposes of Lyra Therapeutics Inc. Common Shares

    Perceptive Advisors LLC, a 10% owner of Lyra Therapeutics Inc., has disposed of common shares in the company. The filing was submitted by Perceptive Advisors LLC and other beneficial owners, accessible via EDGAR. This AI-generated news brief is for informational purposes only and not financial advice. Lyra Therapeutics Inc. published the original content on November 13, 2025.

    Reuters·
    US
    LYRA
    +7.40%
    Reuters·
    US
    LYRA
    +7.40%

    Lyra Therapeutics Faces Financial Challenges Amid Clinical Setbacks

    Lyra Therapeutics, Inc. (LYRA) faces significant financial challenges following a key clinical trial failure. In Q3 2025, the company reported a net loss of $5.98 million, down from $11.87 million the previous year. Cash reserves fell to $22.1 million from $40.6 million, raising concerns about operational sustainability. To address these issues, Lyra is seeking to sublease properties and reduce workforce costs while exploring strategic options to maintain operations and evaluate its lead product candidate, LYR-210.

    Tip Ranks·
    US
    LYRA
    +7.40%
    Tip Ranks·
    US
    LYRA
    +7.40%

    Lyra Therapeutics Q3 net loss narrows

    Lyra Therapeutics reported a Q3 2025 net loss of $6.0 million, down from $11.9 million last year. The company plans a new Phase 3 trial for LYR-210, targeting NDA submission, with cash reserves expected to fund operations into Q3 2026. R&D expenses decreased due to the completion of the ENLIGHTEN 2 trial, while G&A expenses were reduced through lower employee costs. Analysts currently rate the stock as a "hold," with a median 12-month price target of $23.00, significantly above its recent closing price of $4.24.

    Reuters·
    US
    LYRA
    +7.40%
    Reuters·
    US
    LYRA
    +7.40%

    Lyra Therapeutics | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 25 K

    LB filings·
    US
    LYRA
    +7.40%
    LB filings·
    US
    LYRA
    +7.40%
    © 2025 Longbridge｜Disclaimer